IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 76-100 out of 1261.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

Public Release: 18-Mar-2015
Journal of Thoracic Oncology
Early recall rates decline after second round of lung cancer screening
The German Lung Cancer Screening Intervention Trial shows that the early repeat scan rate for suspicious findings decreased by more than 80 percent with the second and subsequent low-dose computed tomography screens, but emphasizes the need to have an organized screening program with the baseline scan available for comparison.

Contact: Murry Wynes
International Association for the Study of Lung Cancer

Public Release: 18-Mar-2015
Gut Microbiota For Health World Summit
Exciting data presented at the 4th Gut Microbiota For Health Summit
On March 14-15, 2015, internationally leading experts in gut microbiota research met in Barcelona, Spain, to present the latest findings and discuss their significance for health and diet.

Contact: Aimee Frank
American Gastroenterological Association

Public Release: 18-Mar-2015
Journal of Pharmacology and Experimental Therapeutics
WSU researchers show how fatty acids can fight prostate cancer
Washington State University researchers have found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings, which are at odds with a 2013 study asserting that omega-3s increase the risk of prostate cancer, point the way to more effective anti-cancer drugs.
Washington State University College of Pharmacy

Contact: Kathryn Meier
Washington State University

Public Release: 18-Mar-2015
Clinical Genitourinary Cancer
NCCS pioneers new drug regimen which reduces toxicities for renal cancer patients
A study led by the Genitourinary oncology team at National Cancer Centre Singapore has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma or cancer that has spread beyond the kidney.

Contact: Ms. Rachel Tan

Public Release: 17-Mar-2015
The link between aspirin, NSAIDs and colon cancer prevention may hinge on genetic variations
The link between taking aspirin, non-steroidal anti-inflammatory drugs, or NSAIDS, and colorectal cancer prevention is well established, but the mechanisms behind the protective effect have not been understood. A new study, co-led by investigators at Fred Hutchinson Cancer Research Center and published March 17 in JAMA, suggests this protection differs according to variations in DNA.
NIH/National Cancer Institute, National Institutes of Health, US Department of Health and Human Services

Contact: Kristen Woodward
Fred Hutchinson Cancer Research Center

Public Release: 17-Mar-2015
Lancet Oncology
Study suggests precision medicine for adrenal cancer
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 17-Mar-2015
Genetic background determines whether aspirin/NSAIDS will reduce colorectal cancer risk
An analysis of genetic and lifestyle data from 10 large epidemiologic studies confirmed that regular use of aspirin or NSAIDs appears to reduce the risk of colorectal cancer in most individuals but also found that a few individuals with rare genetic variants do not share this benefit.
NIH/National Cancer Institute, NIH/National Institute for Diabetes and Digestive and Kidney Diseases

Contact: Katie Marquedant
Massachusetts General Hospital

Public Release: 17-Mar-2015
International Journal of Cancer
Microenvironment provides growth factor for metastasis
When a person has cancer that spreads to the bone and bone marrow, the tissue becomes increasingly fragile, often leading to increased bone resorption. In a surprising discovery, investigators at Children's Hospital Los Angeles found that when neuroblastoma cells metastasize to the bone, there initially occurs an increase in bone deposition, not resorption. They also determined that this process is driven by a chemical messenger called VEGFA.
National Institutes of Health, Ruth L. Kirschstein National Research Service Award

Contact: Ellin Kavanagh
Children's Hospital Los Angeles

Public Release: 17-Mar-2015
Effect of aspirin, NSAIDs on colorectal cancer risk may differ from genetic variations
Among approximately 19,000 individuals, the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an overall lower risk of colorectal cancer, although this association differed according to certain genetic variations, according to a study in the March 17 issue of JAMA.

Contact: Katie Marquedant
The JAMA Network Journals

Public Release: 17-Mar-2015
Study examines diagnostic accuracy of pathologists interpreting breast biopsies
In a study in which pathologists provided diagnostic interpretation of breast biopsy slides, overall agreement between the individual pathologists' interpretations and that of an expert consensus panel was 75 percent, with the highest level of concordance for invasive breast cancer and lower levels of concordance for ductal carcinoma in situ and atypical hyperplasia, according to a study in the March 17 issue of JAMA.

Contact: Susan Gregg
The JAMA Network Journals

Public Release: 17-Mar-2015
Journal of Economic Perspectives
Study: Prices of cancer drugs have soared since 1995
The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist -- but the exact reasons for the cost increases are unclear.
NIH/National Cancer Institute

Contact: Abby Abazorius
Massachusetts Institute of Technology

Public Release: 17-Mar-2015
Nature Structural & Molecular Biology
3-D snapshot of protein highlights potential drug target for breast cancer
One of 15 different polymerases tasked with copying our genetic material, POLQ is singled out in this study for its unique role -- captured in an X-ray crystallography visual -- in DNA repair pathways linked to breast cancer, and therefore, potential as a drug target.
National Institutes of Health, Cancer Prevention and Research Institute of Texas, Grady F. Saunders, Ph.D., Distinguished Research Professorship, NIH/National Cancer Institute, NIH/National Institute of General Medical Sciences

Contact: Jennifer Nachbur
University of Vermont

Public Release: 17-Mar-2015
Researchers describe 5 new species of marine invertebrates
Brazilian researchers described five new species of ascidians, commonly known as sea squirts, ascidians are marine invertebrates that generally form permanently submerged colonies. Exotic molecules obtained from research on ascidians have been explored worldwide for use in combating cancer.
São Paulo Research Foundation

Contact: Samuel Antenor
Fundação de Amparo à Pesquisa do Estado de São Paulo

Public Release: 17-Mar-2015
Clinical Cancer Research
Macrophages may play critical role in melanoma resistance to BRAF inhibitors
Researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
National Institutes of Health, Commonwealth Universal Research Enhancement Program of the Pennsylvania Department of Health, The Wistar Institute Intramural Grants

Contact: Ben Leach
The Wistar Institute

Public Release: 17-Mar-2015
Genetic markers play role in who benefits from aspirin, NSAIDs to lower colon cancer risk
An Indiana University cancer researcher and her colleagues have identified genetic markers that may help determine who benefits from regular use of aspirin and other nonsteroidal anti-inflammatory drugs for lowering one's risk of developing colorectal cancer.
National Institutes of Health

Contact: Michael Schug
Indiana University

Public Release: 16-Mar-2015
Cancer Research
Study identifies 'lethal' subtype of prostate cancer
A University of Colorado Cancer Center study published in the journal Cancer Research defines a new, distinct subtype of 'lethal' prostate cancer marked by the loss of two genes, MAP3K7 and CHD1. Overall about 10 percent of men with prostate cancer will die from the disease. The study shows that of prostate cancer patients with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent prostate cancer, which ultimately leads to death. About 10 percent of all prostate cancers harbor combined MAP3K7-CHD1 deletions.
National Institutes of Health

Contact: Garth Sundem
University of Colorado Denver

Public Release: 16-Mar-2015
Medical Care
Research calls for new policies to support women veterans' health care needs
As more women veterans seek health care in the Veterans Administration (VA) system, effective approaches are needed to ensure that their unique needs are recognized and met. A special April supplement to Medical Care collects new studies from an ongoing research initiative to inform health care policy for women veterans. The journal is published by Wolters Kluwer.

Contact: Connie Hughes
Wolters Kluwer Health

Public Release: 16-Mar-2015
Proceedings of the National Academy of Sciences
Spherical nucleic acids set stage for new paradigm in drug development
A Northwestern University-led research team led is the first to show spherical nucleic acids (SNAs) can be used as potent drugs to effectively train the immune system to fight disease, by either boosting or dampening the immune response. By increasing the immune response toward a specific cell type, SNAs could be used to target anything from influenza to different forms of cancer. If used to suppress the immune response, SNAs could target autoimmune disorders, such as rheumatoid arthritis and psoriasis.
National Institutes of Health, Center for Cancer Nanotechnology Excellence, Defense Advanced Research Projects Agency

Contact: Megan Fellman
Northwestern University

Public Release: 16-Mar-2015
Journal of Cell Biology
Scripps Florida scientists confirm key targets of new anti-cancer drug candidates
In a new study, scientists from the Florida campus of the Scripps Research Institute have confirmed the ribosome assembly process as a potentially fertile new target for anti-cancer drugs by detailing the essential function of a key component in the assembly process.
National Institutes of Health, National Science Foundation, ThinkPink Kids Foundation, PGA National Women's Cancer Awareness Days, Swiss National Foundation

Contact: Eric Sauter
Scripps Research Institute

Public Release: 16-Mar-2015
Nature Communications
Penn vet team points to new colon cancer culprit
Colon cancer is a heavily studied disease -- and for good reason. It is one of the leading causes of cancer-related deaths worldwide, and its numbers are on the rise, from 500,000 deaths in 1990 to 700,000 in 2010. This growth comes despite scientists' ever-increasing knowledge of the genetic mutations that initiate and drive this disease. Now, a team of researchers from the University of Pennsylvania has found evidence of a new culprit in the disease, a protein called MSI2.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Cancer Institute

Contact: Katherine Unger Baillie
University of Pennsylvania

Public Release: 16-Mar-2015
Nature Reviews Immunology
Investigators find window of vulnerability for STIs to infect female reproductive tract
Dartmouth researchers have presented a comprehensive review of the role of sex hormones in the geography of the female reproductive tract and evidence supporting a 'window of vulnerability' to HIV and other sexually transmitted infections.
National Institutes of Health

Contact: Kirk Cassels
The Geisel School of Medicine at Dartmouth

Public Release: 16-Mar-2015
Nature Plants
University of Sydney: Discovery holds promise for gene therapy and agriculture
A key step in understanding the genetic mechanism of plants' environmental adaptability has made in research led by the University of Sydney.

Contact: Verity Leatherdale
University of Sydney

Public Release: 16-Mar-2015
MD Anderson study, new hepatitis C drugs will place strain on health care system
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at the University of Texas MD Anderson Cancer Center.

Contact: Katrina Burton
University of Texas M. D. Anderson Cancer Center

Public Release: 16-Mar-2015
Predicting prostate cancer
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.
National Institutes of Health, John and Carol Walter Center for Urological Health

Contact: Erin Spain
Northwestern University

Public Release: 16-Mar-2015
Scientists find DNA is packaged like a yoyo
A research team led by University of Illinois professor of physics Taekjip Ha has found that DNA uncoils from the nucleosome asymmetrically (uncoiling from one end much more easily) in a recent publication in Cell.
National Science Foundation, National Institutes of Health, Howard Hughes Medical Institute

Contact: Nicholas Vasi
Institute for Genomic Biology, University of Illinois at Urbana-Champaign

Showing releases 76-100 out of 1261.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

  Search News Releases